Fortress Biotech (FBIO) Receives Daily News Sentiment Rating of -0.02

Share on StockTwits

Media stories about Fortress Biotech (NASDAQ:FBIO) have been trending somewhat negative recently, Accern Sentiment reports. Accern ranks the sentiment of press coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Fortress Biotech earned a news sentiment score of -0.02 on Accern’s scale. Accern also assigned news coverage about the biopharmaceutical company an impact score of 46.9561747130402 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

Here are some of the media headlines that may have impacted Accern Sentiment Analysis’s rankings:

Fortress Biotech traded down $0.04, hitting $2.09, on Friday, MarketBeat.com reports. 155,089 shares of the company’s stock traded hands, compared to its average volume of 240,059. The company has a debt-to-equity ratio of 0.68, a current ratio of 2.52 and a quick ratio of 2.52. Fortress Biotech has a 1 year low of $1.41 and a 1 year high of $5.54. The stock has a market cap of $112.68 million, a PE ratio of -1.30 and a beta of 0.10.

Fortress Biotech (NASDAQ:FBIO) last released its earnings results on Friday, August 10th. The biopharmaceutical company reported ($0.50) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.59) by $0.09. Fortress Biotech had a negative return on equity of 68.85% and a negative net margin of 47.97%. The company had revenue of $63.83 million for the quarter, compared to analysts’ expectations of $48.93 million. equities research analysts anticipate that Fortress Biotech will post -2.55 earnings per share for the current year.

Several analysts have issued reports on the company. Zacks Investment Research downgraded Fortress Biotech from a “hold” rating to a “sell” rating in a report on Wednesday, May 16th. HC Wainwright set a $11.00 target price on Fortress Biotech and gave the company a “buy” rating in a research note on Friday. ValuEngine cut Fortress Biotech from a “buy” rating to a “hold” rating in a research note on Monday, July 16th. Finally, JMP Securities set a $11.00 target price on Fortress Biotech and gave the company a “buy” rating in a research note on Monday, May 21st. Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $10.67.

Fortress Biotech Company Profile

Fortress Biotech, Inc develops and commercializes pharmaceutical and biotechnology products. The company develops CNDO-109, a lysate that treats cancer-related and other conditions; tramadol HCl for managing postoperative pain; CAEL-101 for the treatment of amyloid light chain amyloidosis; and CEVA101 for severe traumatic brain injury in children and adults in the United States.

Featured Article: How to Use the New Google Finance Tool

Insider Buying and Selling by Quarter for Fortress Biotech (NASDAQ:FBIO)

Receive News & Ratings for Fortress Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fortress Biotech and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Brokerages Set The Western Union Company  Price Target at $18.25
Brokerages Set The Western Union Company Price Target at $18.25
CaliphCoin Tops One Day Trading Volume of $0.00
CaliphCoin Tops One Day Trading Volume of $0.00
Analysts Anticipate Acadia Healthcare Company Inc  Will Post Earnings of $0.65 Per Share
Analysts Anticipate Acadia Healthcare Company Inc Will Post Earnings of $0.65 Per Share
Somewhat Negative News Coverage Somewhat Unlikely to Impact BIO-key International  Stock Price
Somewhat Negative News Coverage Somewhat Unlikely to Impact BIO-key International Stock Price
Somewhat Favorable Media Coverage Somewhat Unlikely to Impact Burcon Nutrascience  Share Price
Somewhat Favorable Media Coverage Somewhat Unlikely to Impact Burcon Nutrascience Share Price
Zacks: Analysts Anticipate Pool Co.  to Announce $1.57 EPS
Zacks: Analysts Anticipate Pool Co. to Announce $1.57 EPS


Leave a Reply

© 2006-2018 Ticker Report. Google+.